MacroGenics, Inc. (FRA:M55)

Germany · Delayed Price · Currency is EUR

1.424

-0.034 (-2.33%)

Last updated: Feb 23, 2026, 8:06 AM CET

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Developing and Commercializing Monoclonal Antibody Based Therapeutics	149.96M	58.75M	151.94M	77.45M	104.88M
Developing and Commercializing Monoclonal Antibody Based Therapeutics Growth	155.26%	-61.33%	96.19%	-26.16%	63.40%
Total	149.96M	58.75M	151.94M	77.45M	104.88M
Total Growth	155.26%	-61.33%	96.19%	-26.16%	63.40%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States	149.96M	58.75M	151.94M	77.45M	104.88M
United States Growth	155.26%	-61.33%	96.19%	-26.16%	63.40%
Total	149.96M	58.75M	151.94M	77.45M	104.88M
Total Growth	155.26%	-61.33%	96.19%	-26.16%	63.40%

Source: S&P Global Market Intelligence.